Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 1/12/2017 |
| Start Date: | April 2001 |
| End Date: | October 2003 |
A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate
the efficacy of placebo and activated recombinant human factor VII in patients having
undergone allogeneic or autologous stem cell transplantation.
the efficacy of placebo and activated recombinant human factor VII in patients having
undergone allogeneic or autologous stem cell transplantation.
Inclusion Criteria:
- Patients who have undergone allogeneic or autologous stem cell transplantation
Exclusion Criteria:
- Known or suspected allergy to trial product
- Participation in other trials with unapproved drugs or trials with equal or similar
objective
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials